Contribute Try STAT+ Today

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

To secure approval for its first-ever “micro-dystrophin” gene therapy for Duchenne muscular dystrophy, Sarepta Therapeutics needs to deliver a positive outcome from a randomized, placebo-controlled clinical trial — something the biotech has never accomplished before, despite already winning approval for two drugs to treat Duchenne. Sarepta is hoping to show that its one-time, potentially curative treatment called SRP-9001 can improve muscle function in patients with Duchenne. The study’s readout is expected early in the quarter, perhaps in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.